Clinical and laboratory improvement after intravenous immunoglobulin in drug reaction with eosinophilia and systemic symptoms

J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):107-10. doi: 10.1016/j.jaip.2013.11.008.

Authors

Violeta Régnier Galvão¹, Marcelo Vivolo Aun¹, Jorge Kalil¹, Mariana Castells², Pedro Giavina-Bianchi³

Affiliations

¹ Division of Clinical Immunology and Allergy, Department of Internal Medicine, University of São Paulo Medical School, São Paulo, São Paulo, Brazil.
² Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.
³ Division of Clinical Immunology and Allergy, Department of Internal Medicine, University of São Paulo Medical School, São Paulo, São Paulo, Brazil. Electronic address: [email protected].

PMID: 24565781
DOI: 10.1016/j.jaip.2013.11.008

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Anticonvulsants / adverse effects*
Biopsy
Drug Hypersensitivity Syndrome / diagnosis
Drug Hypersensitivity Syndrome / drug therapy*
Drug Hypersensitivity Syndrome / etiology
Drug Hypersensitivity Syndrome / immunology
Drug Hypersensitivity Syndrome / virology
Drug Resistance
Epstein-Barr Virus Infections / complications
Epstein-Barr Virus Infections / immunology
Epstein-Barr Virus Infections / virology
Esophagoscopy
Female
Humans
Immunoglobulins, Intravenous / therapeutic use*
Middle Aged
Phenytoin / adverse effects*
Risk Factors
Tomography, X-Ray Computed
Treatment Outcome

Substances

Adrenal Cortex Hormones
Anticonvulsants
Immunoglobulins, Intravenous
Phenytoin